JP2017522886A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522886A5
JP2017522886A5 JP2017504353A JP2017504353A JP2017522886A5 JP 2017522886 A5 JP2017522886 A5 JP 2017522886A5 JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017522886 A5 JP2017522886 A5 JP 2017522886A5
Authority
JP
Japan
Prior art keywords
antibody
seq
htt
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/067327 external-priority patent/WO2016016278A2/en
Publication of JP2017522886A publication Critical patent/JP2017522886A/ja
Publication of JP2017522886A5 publication Critical patent/JP2017522886A5/ja
Pending legal-status Critical Current

Links

JP2017504353A 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン(htt)抗体及びその使用 Pending JP2017522886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179004.8 2014-07-29
EP14179004 2014-07-29
PCT/EP2015/067327 WO2016016278A2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (htt) antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096056A Division JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン(htt)抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2017522886A JP2017522886A (ja) 2017-08-17
JP2017522886A5 true JP2017522886A5 (https=) 2018-10-18

Family

ID=51225442

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504353A Pending JP2017522886A (ja) 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン(htt)抗体及びその使用
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン(htt)抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン(htt)抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン(htt)抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン(htt)抗体及びその使用

Country Status (11)

Country Link
US (3) US10556946B2 (https=)
EP (2) EP4406549A3 (https=)
JP (3) JP2017522886A (https=)
KR (1) KR102643395B1 (https=)
CN (2) CN113651887A (https=)
AU (3) AU2015295441B2 (https=)
CA (1) CA2954738A1 (https=)
EA (1) EA201790165A1 (https=)
IL (2) IL250180A0 (https=)
MX (3) MX391037B (https=)
WO (1) WO2016016278A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP4406549A3 (en) * 2014-07-29 2025-01-08 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
US11851487B2 (en) * 2019-04-01 2023-12-26 Rensselaer Polytechnic Institute Methods and systems for detecting peptide aggregates
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
EP4041308A1 (en) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
CN111909265B (zh) * 2020-08-25 2022-02-11 中国人民解放军军事科学院军事医学研究院 一种结合破伤风毒素重链c端结构域的人源抗体及应用
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CN114334076B (zh) * 2021-12-23 2025-03-21 华中科技大学 一种药食同源中药玉竹的重金属概率风险评估方法及系统
CN120476138A (zh) * 2022-12-07 2025-08-12 阿乐凯抗体治疗有限公司 抗亨廷顿蛋白抗体

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2116280A1 (en) 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
ES2242997T3 (es) 1997-03-14 2005-11-16 Biogen Idec Inc. Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo.
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1999006838A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel method of detecting amyloid-like fibrils or protein aggregates
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
EP1340088B1 (en) 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP2319936A3 (en) * 2001-02-15 2012-10-17 The University of Chicago Yeast screens for agents affecting protein folding
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7375194B2 (en) * 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
WO2004101787A1 (ja) * 2003-05-14 2004-11-25 Japan Science And Technology Agency ハンチンチン遺伝子の発現抑制
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
KR20120017469A (ko) * 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
WO2013013025A2 (en) * 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
EP3071598B1 (en) * 2013-05-29 2021-07-07 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
WO2016005547A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
NZ728041A (en) * 2014-07-10 2023-01-27 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington’s disease
EP4406549A3 (en) 2014-07-29 2025-01-08 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2017522886A5 (https=)
US11685776B2 (en) Engineered heterodimeric proteins
JP2013535191A5 (https=)
JP2012501670A5 (https=)
FI3826667T3 (fi) Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
RU2017123549A (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP2014528695A5 (https=)
JP2017114866A5 (https=)
JP2018502561A5 (https=)
JP2017205118A5 (https=)
JP2015505665A5 (https=)
JP2018532766A5 (https=)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2012010714A5 (https=)
JP2021500916A5 (https=)
JP2014158485A5 (https=)
JP2016516400A5 (https=)
IL261666B1 (en) Binding proteins and methods of use thereof
JP2015530971A5 (https=)
WO2015032906A4 (en) Cd70-binding peptides and method, process and use relating thereto
JP2014503178A5 (https=)
JP2018505681A5 (https=)
JP2018522888A5 (https=)
JP2010526028A5 (https=)